呼吸器・免疫内科学

白山　敬之Shiroyama Takayuki M.D., PhD

略歴

所属学会

日本内科学会、日本呼吸器学会、日本呼吸器内視鏡学会、日本肺癌学会、日本化学療法学会、日本静脈経腸栄養学会

資格等

日本内科学会認定内科医、日本内科学会総合内科専門医、内科指導医、呼吸器専門医・指導医、気管支鏡専門医・指導医、日本呼吸器学会推薦インフェクションコントロールドクター、がん治療認定医、Scientific Reports誌 Editorial Board Member

臨床研究関連

主に肺癌を中心とした臨床研究に取り組んでおり、大阪大学およびその関連グループの先生方と多数の共同研究を行ってきました。これまでに英語論文を共著で130本以上発表しており、そのうち約40本は筆頭著者または責任著者として執筆しています（ケースレポート・レターを含む）。日々の診療と研究を通じて、目の前の患者さんにより良い治療を届けられるよう、今後も研鑽を続けてまいります。

主要論文

• Yanagisawa A, Shiroyama T,* Miyake K, et al. Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report. J Thorac Oncol. 2025 May;20(5):676-679. [*Corresponding author]
• Shintani T, Shun YT, Toyozumi Y, et al. MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma. Sci Rep. 2024 Oct 18;14(1):24429.
• Matsumoto K, Yamamoto Y, Shiroyama T*, et al. Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study. Target Oncol. 2024 Sep;19(5):757-767. [*Corresponding author]
• Nishio M, Murakami S, Kawakami H, et al. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer Res Commun. 2024 Jan 29;4(1):226-235.
• Matsumoto K, Shiroyama T*, Tamiya M, et al. Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study. Cancer Immunol Immunother. 2024 Jan 4;73(1):4. [*Corresponding author]
• Kinehara Y, Shiroyama T*, Tamiya A, et al. Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC. JTO Clin Res Rep. 2023 Oct 12;4(11):100586. [*Corresponding author]
• Kuge T, Shiroyama T*, Tamiya A, et al. Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC. JTO Clin Res Rep. 2023 Mar 23;4(5):100505. [*Corresponding author]
• Matsumoto K, Shiroyama T*, Kuge T, et al. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. Transl Lung Cancer Res. 2022 Sep;11(9):1835-1846. [*Corresponding author]
• Wang QS, Edahiro R, Namkoong H, et al. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force. Nat Commun. 2022 Aug 22;13(1):4830.
• Namkoong H, Edahiro R, Takano T, et al. DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature. 2022 Sep;609(7928):754-760.
• Matsumoto K, Shiroyama T*, Yamamoto Y, et al. Impact of the Treatment Line on the Risks and Benefits of Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer and Interstitial Lung Disease. Chest. 2022 Jul;162(1):e67-e69. [*Corresponding author]
• Otsuka T, Nishida S, Shibahara T, et al. CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. BMC Cancer. 2022 Jul 7;22(1):744.
• Noda Y, Shiroyama T*, Masuhiro K, et al. Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer. Sci Rep. 2022 May 25;12(1):8881. [*Corresponding author]
• Yaga M, Shiroyama T*, Hirata H, et al. Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 Mar;23(2):e116-e117. [*Corresponding author]
• Matsumoto K, Shiroyama T*, Kuge T, et al. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2021 Dec;162:175-184. [*Corresponding author]
• Yamamoto Y, Shiroyama T*, Hirata H, et al. Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19. J Med Virol. 2022 Mar;94(3):1067-1073. [*Corresponding author]
• Niitsu T, Shiroyama T*, Hirata H, et al. Cytomegalovirus infection in critically ill patients with COVID-19. J Infect. 2021 Oct;83(4):496-522. [*Corresponding author]
• Tamiya M, Tamiya A, Suzuki H, et al. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. Invest New Drugs. 2021 Aug;39(4):1106-1112.
• Adachi Y, Shiroyama T*, Yamaguchi Y, et al. Predicting recurrence of respiratory failure in critically ill patients with COVID-19: A preliminary study. J Infect. 2021 May;82(5):e33-e35. [*Corresponding author]
• Shiroyama T, Hirata H, Nagatomo I, et al. Pulmonary metastases of lung adenocarcinoma mimicking COVID-19 pneumonia. J Thorac Dis. 2020 Oct;12(10):6125-6126.
• Edahiro R, Shiroyama T*, Hijiki S, et al. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment. Lung Cancer. 2020 Feb;140:116-117. [*Corresponding author]
• Masuhiro K, Shiroyama T*, Nagatomo I, et al. Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment. J Thorac Oncol. 2019 May;14(5):e108-e109. [*Corresponding author]
• Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci Rep. 2019 Feb 21;9(1):2447.
• Shiroyama T, Suzuki H, Tamiya M, et al. Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Res. 2018 Aug;38(8):4723-4729.
• Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 2018 Jan;7(1):13-20.
• Tamiya M, Tamiya A, Shiroyama T, et al. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naive advanced non-squamous non-small cell lung cancer with EGFR mutations. Invest New Drugs. 2017 Nov 4. doi: 10.1007/s10637-017-0527-z.
• Shiroyama T, Tamiya M, Minami S, et al. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study. Cancer Chemother Pharmacol. 2017 Sep;80(3):461-467.
• Shiroyama T, Okamoto N, Suzuki H, et al. Usefulness of high suction pressure for sufficient tissue collection during endobronchial ultrasound guided transbronchial needle aspiration. PLoS One. 2013 Dec 5;8(12):e82787.
• Tamiya A, Tamiya M, Shiroyama T, et al. Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol. 2013 Apr;24(4):980-5.
• Shiroyama T, Kijima T, Komuta K, et al. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer. Cancer Chemother Pharmacol. 2012 Dec;70(6):783-9.
• Shiroyama T, Komuta K, Imamura F, et al. Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer. 2011 Oct;74(1):85-8.

新聞報道・その他